Adachi S, Itani Y, Ito K, Noda T, Shintani M, Saito K, Furukawa N, Tomii Y
Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo 663, Japan.
Oncol Rep. 2001 Jan-Feb;8(1):27-31.
We performed a dose-escalation study of carboplatin combined with a fixed dose of intraperitoneal cisplatin and G-CSF in patients with epithelial ovarian cancer, and analyzed the progression-free and overall survival. Six of the patients who entered the study with stage IC and II disease are still alive with no evidence of disease. The five-year survival rate was 61% for the 18 patients with stage III and IV disease; progression-free survival over 5 years was 32%. Our results show this to be an effective treatment regimen for epithelial ovarian cancer. Prognosis is good with this combined carboplatin/cisplatin/G-CSF therapy, especially for those patients with microscopic or no residual disease.
我们对上皮性卵巢癌患者进行了一项卡铂联合固定剂量腹腔内顺铂及粒细胞集落刺激因子（G-CSF）的剂量递增研究，并分析了无进展生存期和总生存期。6例以IC期和II期疾病入组研究的患者仍存活，且无疾病证据。18例III期和IV期疾病患者的五年生存率为61%；5年以上的无进展生存率为32%。我们的结果表明这是一种治疗上皮性卵巢癌的有效治疗方案。这种卡铂/顺铂/G-CSF联合治疗的预后良好，尤其是对于那些微小残留或无残留疾病的患者。
Zotero 插件